Tag:

Vivus

Latest Headlines

Latest Headlines

Endo plots a double-sized salesforce, new DTC push for Stendra relaunch

Not satisfied with the way its new purchase Auxilium had handled Stendra marketing, Endo plans to relaunch the erectile dysfunction med, which it sells in partnership with Vivus. Endo is doubling the size of the Stendra salesforce, rolling out a new DTC effort, and keeping a close eye on inventory levels, which had built up too much for its taste.

Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC

Upon buying up Auxilium--which markets Vivus' erectile dysfunction drug Stendra--Endo decided wholesale inventory levels weren't where they ought to be. Its solution? A relaunch of the drug, complete with a new salesforce and DTC efforts.

Analyst: Vivus generic threats a positive for obesity market

No drugmaker wants a generic challenger for a product it relies on--and certainly not two generics challengers. But in the case of Vivus, which has sued Actavis and now Teva over patent infringement for weight-loss drug Qsymia, the generic interest could be an "incremental positive," one analyst believes.

Vivus to slash obesity salesforce by one-third, turn to digital instead

Critics say Vivus has lacked the marketing muscle to build up its weight-loss med Qsymia ever since it chose to launch without a large commercial partner. And now, the company has chosen to shrink its salesforce by a third, with about 50 reps headed for the door.

FDA backs ED upstart Stendra as a fast-acting alternative to Viagra

Companies have been studying Stendra for some sort of competitive edge. Now, they may have found one: The FDA backed the ED pill as a fast-acting treatment, taken 15 minutes before sex. Previously, the directions prescribed a 30-minute lead time.

Vivus hits Actavis with Qsymia patent-infringement lawsuit

Weak Qsymia sales have been the all-important issue for Vivus since the highly anticipated obesity therapy stumbled out of the gate, inspiring an all-out proxy war that wreaked havoc on the company's boardroom. And the California company isn't about to cede what market share it does have to Actavis--at least, not without a fight.

Mystery investment fund eyes $640M bid for struggling obesity drug maker Vivus

Vivus has been through a lot over the past year, including an all-out proxy war, a myriad of exec exits and, most recently, a generic threat from Actavis to its flailing obesity drug Qsymia. And now? It appears to have an interested buyer, according to a regulatory filing.

Actavis slaps struggling Vivus with generic threat

After a botched launch for obesity drug Qsymia, a bitter proxy war, a mass exodus of its directors and management and a continued sales struggle, the last thing Vivus needs is a generic threat. But thanks to Actavis, that's exactly what it's getting.

Vivus needs more than boardroom shuffling to keep up with Arena's Belviq

One pre-First Manhattan Co.-settlement Vivus director standing for re-election at the company's annual meeting, that is. The Mountain View, CA-based drugmaker announced Tuesday in a regulatory filing that J. Martin Carroll, Mark Logan and Robert Wilson would not seek to retain their board positions.

Can Auxilium's ED hopeful Stendra score with provocative March Madness ads?

Auxilium is marketing Vivus' new erectile dysfunction pill Stendra with a jazzy, suggestive promo video during March Madness, when millions of men are glued to the games.